Therapeutic Solutions International, INC.: directors' dealings · United States · SEC (Form 4)

About Therapeutic Solutions International, INC.

Therapeutic Solutions International, Inc. (ticker: TSOI) is a U.S.-based micro-cap healthcare company associated with the American over-the-counter market rather than NYSE/NASDAQ at this stage. The company is headquartered in the United States, with SEC filings indicating a corporate move to Elk City, Idaho. In business terms, TSOI positions itself as a biotech and medical-solutions developer focused on immunomodulation, cell-based therapies, and programs linked to oncology and inflammatory diseases. Its SEC disclosures suggest a very small operating base, significant reliance on external financing, and the going-concern and dilution risks that are common among early-stage biopharma names. From a business-line perspective, the company has historically communicated around several development themes: stem-cell-based therapeutic candidates, immune-system modulation, and clinical or preclinical applications in severe disease settings. One of the most frequently cited assets is JadiCell™, described by the company as a flagship cell-therapy program, alongside additional initiatives tied to cancer and other high-unmet-need indications. TSOI’s competitive position remains highly uncertain and depends on clinical validation, regulatory progress, and its ability to fund research and development over time. In this respect, it is not comparable to large-cap pharmaceutical companies with diversified commercial franchises; instead, its equity story is driven primarily by milestone events and binary outcomes. Geographically, the company appears predominantly U.S.-centric. The SEC filings point to an operational footprint concentrated in Idaho, with historical references to California in earlier corporate documents. There is no clear evidence of a broad international commercial platform comparable to that of a global drug manufacturer. Any broader geographic reach would likely come through potential partnerships, licensing, or future development relationships rather than an established multinational sales network. Recent highlights seen in SEC filings include insider transactions reported on Form 4, which often attract close attention in this type of stock. The company’s regulatory documents also underscore ongoing liquidity pressure, dependence on future capital raises, and the need to sustain operations while advancing its development pipeline. For French-speaking investors, TSOI should therefore be viewed as a highly speculative U.S. biotech micro-cap, with value anchored more in clinical and financing catalysts than in traditional earnings-based valuation metrics.